I would wait till 4th quarter before passing judgment on AV101. Nothing has changed except the stock price due to an over reaction based on a statistically meaningless trial involving only 19 patients the had an average of 9 yrs of chronic depression. It appears that no drug has been effective. Furthermore, that study started in 2015 and took 3 yrs to even enroll those patients and the study was a mono therapy as opposed to an adjunctive treatment. AV101 is still fast tracked for pain and has 2 other drugs in the pipeline, both nasal drugs.
The conference was about TAUGs products and from what I could see there was plenty of interest by funds in throwing money at CBD companies. Just a guess, but I think the balance sheet will be fine
News 
Market Data 
Discover 
